Beigene, Ltd. (NASDAQ:ONC - Get Free Report) insider Lai Wang sold 1,402 shares of Beigene stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $252.39, for a total transaction of $353,850.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Beigene Stock Down 0.4%
NASDAQ:ONC traded down $1.01 during midday trading on Wednesday, hitting $262.41. The company had a trading volume of 282,581 shares, compared to its average volume of 449,112. The firm has a market cap of $31.06 billion, a P/E ratio of -31.85, a PEG ratio of 7.73 and a beta of 0.30. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. Beigene, Ltd. has a 52-week low of $141.31 and a 52-week high of $287.88. The stock has a fifty day simple moving average of $238.58.
Beigene (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 earnings per share for the quarter, beating analysts' consensus estimates of ($0.71) by $1.93. The company had revenue of $1.12 billion for the quarter, compared to analysts' expectations of $1.12 billion. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. As a group, research analysts forecast that Beigene, Ltd. will post -5.82 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on ONC shares. Guggenheim lifted their price objective on Beigene from $348.00 to $350.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. TD Securities reiterated a "buy" rating and issued a $334.00 target price on shares of Beigene in a research note on Thursday, April 24th. Wall Street Zen raised shares of Beigene from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Royal Bank of Canada dropped their price objective on Beigene from $312.00 to $311.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. Finally, Bank of America raised Beigene from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $207.00 to $320.00 in a research note on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $319.00.
Get Our Latest Research Report on Beigene
About Beigene
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
See Also
Before you consider Beigene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beigene wasn't on the list.
While Beigene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
